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ABSTRACT
Introduction Shoulder pain is common and the 
prognosis is often unfavourable. Dutch guidelines on the 
treatment of shoulder pain in primary care recommend a 
corticosteroid injection or a referral to exercise therapy, 
if initial pain management fails and pain persists. 
However, evidence of the effectiveness of a corticosteroid 
injection compared with exercise therapy, especially in 
the long term, is limited. This trial will assess the clinical 
effectiveness and cost effectiveness of a corticosteroid 
injection compared with physiotherapist- led exercise 
therapy over 12 months follow- up in patients with 
shoulder pain in primary care.
Methods and analysis The SIX Study is a multicentre, 
pragmatic randomised clinical trial in primary care. A 
total of 213 patients with shoulder pain, aged ≥18 years 
presenting in general practice will be included. Patients 
will be randomised (1:1) into two groups: a corticosteroid 
injection or 12 sessions of physiotherapist- led exercise 
therapy. The effect of the allocated treatment will be 
assessed through questionnaires at 6 weeks and after 
3, 6, 9 and 12 months. The primary outcome is patient’s 
reported shoulder pain- intensity and function, measured 
with the Shoulder Pain and Disability Index, over 12 
months follow- up. Secondary outcomes include cost 
effectiveness, pain- intensity, function, health- related 
quality of life, sleep quality, patient’s global perceived 
effect, work absence, healthcare utilisation and adverse 
events. Between group differences will be evaluated using 
a repeated measurements analysis with linear effects 
models. A cost- utility analysis will be performed to assess 
the cost effectiveness using quality- adjusted life years 
from a medical and societal perspective.
Ethics and dissemination This study was approved by 
the Medical Ethics Committee of Erasmus MC University 
Medical Center Rotterdam (MEC 2020-0300). All 
participants will give written informed consent prior to data 
collection. The results from this study will be disseminated 
in international journals and implemented in the primary 
care guidelines on shoulder pain.
Trial registration number Dutch Trial Registry (NL8854).
INTRODUCTION
Background and rationale
Shoulder pain is the third most common 
musculoskeletal complaint in primary 
healthcare.1–3 The estimated incidence is 
reported at 30.3 per 1000 person- years.3 The 
prognosis for shoulder pain is often unfa-
vourable. Only 50% of people presenting 
with a new episode of shoulder pain in 
primary care show complete recovery within 
6 months.4 In general, apart from pain, 
patients with shoulder pain report having 
functional limitations which can reach a 
level of severity whereby they preclude 
work- related tasks.5 Work absence and treat-
ment of shoulder pain generate high costs 
to society and healthcare.6 7 A recent cost- 
estimation study for patients with shoulder 
pain consulting in primary care in Sweden 
estimated the mean annual costs at €4139 
Strengths and limitations of this study
 ► This is a large pragmatic randomised controlled trial 
that aims to evaluate two treatment options recom-
mended by the guidelines in the management of 
persistent shoulder pain in general practice, a corti-
costeroid injection compared with exercise therapy.
 ► In addition to the clinical effectiveness, a cost- 
effectiveness analysis will be performed for both 
treatments.
 ► This study has a long follow- up period of 12 months, 
allowing for the analysis of the long- term (cost- )ef-
fectiveness of both treatments.
 ► The pragmatic nature of this trial has its drawbacks, 
however, it will provide a true reflection of both 
treatments applied in current practice.
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per patient, with sick leave accounting for more than 
80% of the total costs.7
Guidelines for the management of shoulder pain 
provide treatment options based on the initial diagnosis 
of the general practitioner (GP) and the severity of the 
pain.8 9 The recommended management options in the 
guidelines are focused on controlling pain and restoring 
or maintaining shoulder function. The recently updated 
primary care guideline for shoulder pain, issued by the 
Dutch College of General Practitioners (NHG) in 2019, 
recommends a stepped- care approach. In the first step, 
GPs are advised to start the treatment with advice and, 
if necessary, prescribe analgesics. If pain persists, the 
GP is recommended to either prolong or adjust analge-
sics, administer a local corticosteroid injection in case of 
severe pain or refer the patient to a physiotherapist for 
exercise therapy in case of (impending) dysfunction.8 
Although the guideline recommends exercise therapy or 
corticosteroid injection when shoulder pain persists, the 
guideline acknowledges the lack of evidence to favour 
one option over the other.
A systematic review by Steuri et al on randomised 
controlled trials (RCTs) comparing corticosteroid injec-
tion(s) to exercise therapy showed that injections have 
statistically significant, but small effect on pain in the short 
term, generally within 6 weeks after the intervention, but 
not at longer follow- up time intervals (3–6 months).10 
Given the low quality of most of the included studies and 
high level of heterogeneity, the authors concluded that 
larger, high quality trials are required. Moreover, the 
authors call for health economic evaluations alongside 
such trials to assess comparative cost effectiveness and 
cost utility. A similar call came from the Cochrane review 
by Page et al on manual therapy and exercise for rotator 
cuff disease; ‘high quality RCTs are needed to establish 
the benefits and harms of exercise interventions that 
reflect actual practice, compared with placebo, no inter-
vention or active interventions with evidence of benefit 
(eg, glucocorticoid injection)’.11
Given the high incidence and costs associated with 
shoulder pain and the lack of high quality evidence to 
underpin current clinical practice and guideline recom-
mendations, the recently published National Research 
Agenda by the NHG listed research on the effectiveness 
of corticosteroid injections for shoulder pain in general 
practice as a top priority.12 We have therefore designed 
an RCT to compare the clinical and cost effectiveness of 
corticosteroid injections and physiotherapist- led exercise 
therapy as primary care management interventions for 
patients with shoulder pain.
Objectives
The primary objective of the Shoulder Injection and eXer-
cise (SIX) trial is to compare the clinical effectiveness of a 
local corticosteroid injection to physiotherapist- led exer-
cise therapy for shoulder pain in primary care over 12 
months of follow- up. The main secondary objective is to 
compare the cost effectiveness of both treatments over a 
12- month follow- up period.
METHODS AND ANALYSIS
Trial design/study setting
The study is a randomised, multicentre, open label, 
parallel group, pragmatic clinical trial. Patients will 
be recruited in Dutch general practices. GPs will select 
patients presented with shoulder pain who are suitable 
for both a local corticosteroid injection and physiothera-
pist- led exercise therapy. GPs will refer these patients to 
the SIX research team, who will further assess all poten-




 ► Patient has contacted their GP with shoulder pain 
due to subacromial pain syndrome or glenohumeral 
disorders.
 ► Aged 18 years or older.
 ► Qualified for both a local corticosteroid injection and 
physiotherapist- led exercise therapy, as indicated by 
the GP.
 ► Able to understand spoken and written Dutch 
language.
Exclusion criteria
 ► Shoulder pain due to recent serious trauma, malig-
nancy, systemic rheumatologically disease, neurolog-
ical or cardiac disease.8
 ► Shoulder pain due to instability of the glenohumeral 
joint, disorders of the acromioclavicular or sternocla-
vicular joint, or neck pain with additional shoulder 
pain.
 ► Treatment of the affected shoulder with corticos-
teroid injection or physiotherapy in the last 6 months.
 ► A history of serious shoulder trauma, such as frac-
tures, ruptures, luxation or surgery.
 ► Contraindications for corticosteroid injection.
 ► Current use of oral corticosteroids.
For participants with bilateral shoulder pain, the most 
painful shoulder will be taken as the study shoulder.
Parallel cohort study
Patients with shoulder pain who are not eligible for trial 
participation or patients who are eligible but do not want 
to be randomised, for example, due to strong treatment 
preferences, will be invited to participate in a parallel 
cohort study. With their consent, these patients will be 
assessed using the same outcome measures at similar time 
points. In addition, these patients will complete a question-
naire regarding their treatment preferences and reasons 
for not wanting to participate in the trial (if applicable) at 
baseline. This information will provide important infor-
mation regarding the recruitment process by indicating 
if and why recruitment may be suboptimal or failing. 
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Furthermore, the parallel cohort study will provide the 
unique possibility to compare baseline characteristics of 
randomised participants to those who were not eligible 
or not willing to be randomised and outcomes following 
their (preferred) treatment.
We anticipate recruiting around 600 patients to this 
parallel cohort study. All cohort participants who are not 
eligible for the RCT will be informed that if the initial 
GP treatment fails and they consider re- consultation, they 
are potentially eligible for the RCT. They can contact the 
SIX research team for receiving additional information 




The corticosteroid injection will be delivered by the GP. 
The corticosteroid injection will consist of 40 mg triam-
cinolone acetonide (Kenacort- A 40), possibly in combi-
nation with a local anaesthetic agent, lidocaine 10 mg, 
at the discretion of the GP in accordance with the NHG 
guideline for shoulder pain.8
The site of the injection, subacromial or intra- articular, 
will depend on the initial diagnosis of the GP. Subacro-
mial injections will be administered to participants diag-
nosed with subacromial pain syndrome and intra- articular 
injections on participants with glenohumeral joint pain. 
GPs are advised to follow the instructional videos on 
subacromial and intra- articular injection published by 
the NHG.13 All participating GPs will be invited for an 
optional shoulder injection training by an experienced 
doctor of orthopaedic medicine at the Erasmus MC.
Consultations with the GP will be coordinated so that 
participants typically receive their injection within 1 week 
of randomisation. In line with the guideline, a maximum 
of two injections will be permitted per patient, with the 
second injection, when considered necessary, offered 2–4 
weeks after the first injection. Any participant receiving 
a second injection will have the date of administration 
recorded in their case report form.
Physiotherapist-led exercise therapy
Participants randomised to physiotherapist- led exercise 
therapy will be referred to one of the local physiother-
apists. Preferably the physiotherapist is affiliated with 
the Dutch Shoulder Network (SNN). The SNN is an 
umbrella organisation for regional shoulder networks of 
physiotherapist practices. All affiliated physiotherapists 
have to complete a 2- day entry course on shoulder pain, 
accredited by the Royal Dutch Society for Physiotherapy 
(KNGF).
The exercise therapy will consist of a maximum of 12 
treatments of around 30 min under the supervision of 
the physiotherapist over a course of 12–14 weeks. In addi-
tion, all participants will receive home- based exercise at 
the discretion of the physiotherapist. The intensity of the 
exercise is based on tissue irritability and the capacity of 
the patient. Pain during or after exercise is allowed, as 
long as there is no night- time pain and the pain returns to 
pre- training levels within 24 hours. Physiotherapist will be 
requested not to use massage, laser therapy, ultrasound 
therapy, transcutaneous electrical nerve stimulation, dry 
needling or acupuncture, given lack of evidence for effec-
tiveness.14 All participating physiotherapists will receive a 
brief guideline developed in cooperation with the SNN 
describing the criteria for exercise therapy.
Co-interventions
This is a pragmatic clinical trial designed to evaluate 
the effectiveness of corticosteroid injections compared 
with physiotherapist- led exercise therapy for shoulder 
pain in real- life routine practice conditions. Therefore, 
participants will be instructed to continue their usual 
medication as discussed with their GP. Co- interventions 
after randomisation will be allowed and will be moni-
tored through medical record review and questionnaires. 
This includes cross- over between interventions, which is 
estimated to occur in 20% of participants based on the 
number of patients receiving an injection and referral for 
exercise therapy in the ‘usual care’ treatment arm of a 
recent RCT.15
Outcomes
Table 1 shows an overview of the time schedule of enrol-
ment, interventions and all assessments for participants. 
The selection of outcome measures has been based on the 
core outcome set published by The Outcome Measures in 
Rheumatology (OMERACT) Shoulder Working Group.16 
The primary outcome is shoulder pain- intensity and func-
tion measured using the Shoulder Pain and Disability 
Index (SPADI) total score over 12 months post randomi-
sation.17 The SPADI is the most commonly used measure 
to assess pain- intensity and disability.18 The Dutch version 
of the SPADI has good psychometric properties.19 20
Secondary outcomes include incremental costs per 
quality- adjusted life year (QALY) gained, using both the 
medical as well as the societal perspective, over 12 months 
post randomisation. Medical costs will be measured using 
the Medical Cost Questionnaire (MCQ) and societal costs 
will be measured using the Productivity Cost Question-
naire (PCQ).21 QALY will be measured using the five- level 
version of the well- validated EuroQol Five- Dimensional 
Questionnaire (EQ- 5D- 5L) score.22
Other secondary outcomes will be clinical effectiveness 
and cost effectiveness of the randomised treatments in 
the short term (6 weeks, 3 months) and medium term (6 
months, 9 months). In addition, secondary outcomes will 
include subdomains (pain and function) of the SPADI, 
health- related quality of life (EQ- 5D- 5L), sleep quality 
measured with the Sleep Quality Scale,23 participant’s 
perceived recovery using the global perceived effect ques-
tionnaire,16 work absence as measured by the PCQ, health-
care utilisation as measured by the MCQ, side effects 
assessed at short term post randomisation and serious 
adverse events (SAEs) occurring post randomisation.
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Sample size
The target sample size is 85 participants in each trial 
group. This is based on 90% power and a 0.05 two- sided 
statistical significance to detect a minimally clinically 
important difference of ten points on the SPADI total 
scale,24 using a conservative estimation of a baseline SD 
of 20.25 Accounting for a potential loss to follow- up at 12 
months of 20%, this will require a total of 213 patients to 
be randomised to the intervention groups.
Recruitment
All patients (≥18 years old) consulting their GP for 
shoulder pain who are suitable for both a local cortico-
steroid injection and physiotherapist- led exercise therapy 
can be invited by their GP to participate in this study. 
These patients will be informed on the trial by the GP and 
are advised to contact the research team. The research 
team will provide further information on the trial and if 
the patient confirms their interest to participate in the 
trial, eligibility will be checked and the informed consent 
procedure will be completed. After the participant has 
completed the baseline questionnaire, the patient will be 
randomised by the research team. The patient and the 
GP will be notified on the randomisation result by the 
research ream.
All other patients (eg, wait- and- see policy or prescrip-
tion of analgesics) will be invited to participate in the 












Enrolment           
  Diagnosis X         
  Eligibility screening X         
  Informed consent X         
  Randomisation†   X       
Interventions           
  Corticosteroid injection†   X       
  Physiotherapist- led exercise therapy†       
Assessments           
  Sociodemographics   X       
  Current shoulder episode (location, duration, cause, 
course, stiffness)
  X       
  Previous shoulder episodes (history, treatments)   X       
  Other current pain locations (pain manikin)   X       
  Other relevant medical issues   X       
  Psychological prognostic factors (HADS, FABQ)   X       
  Current medical use for the shoulder pain   X       
  Treatment preferences   X       
  Treatment expectations   X       
Outcomes           
  Pain and function (SPADI)   X X X X
  Medical costs (MCQ)     X X X
  Global perceived effect (GPE)     X X X
  Productivity costs (PCQ)     X X X
  Health- related quality of life (EQ- 5D- 5L)   X X X X
  Sleep quality (SQS)   X X X X
  Side effects     X X   
  Serious adverse events (SAEs)     X X X
*At these time points the indicated outcome measures will be repeated.
†Randomisation occurs after baseline measurements are taken.
EQ- 5D- 5L, five- level version of the well- validated EuroQol Five- Dimensional Questionnaire; FABQ, Fear- avoidance Beliefs Questionnaire; 
HADS, Hospital Anxiety and Depression Scale; MCQ, Medical Cost Questionnaire; PCQ, Productivity Cost Questionnaire; SPADI, Shoulder 
Pain and Disability Index; SQS, Sleep Quality Scale.
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parallel cohort study. These patients will be invited 
through two weekly searches of the medical records of 
participating GP practices. All cohort participants will be 
informed that if the initial GP treatment fails and they 
consider re- consultation, they are potentially eligible for 
the RCT (figure 1).
Accounting for a 25% willingness of patients to partic-
ipate in the RCT and in the cohort, a 50% willingness 
of participants in the cohort to enter the trial if initial 
treatment fails and a 25% loss due to not eligible for the 
trial, 2430 patients need to be invited to participate in 
either the trial or the cohort over the 18 months period. 
On average, a fulltime Dutch GP has around 2095 regis-
tered patients.26 With an incidence rate of 30.3 per 1000 
person- years in the Netherlands,3 it is expected that a full-
time GP sees around six patients with a new episode of 
shoulder pain per month, which results in 23 GPs needed 
for this study. However, taking in account Lasagna’s law,27 
we expect to need at least 46 GPs to ensure the total 
sample size.
Figure 1 Consort flowchart of recruitment. GP, general practitioner.
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Allocation
The Erasmus MC Clinical Trial Center, who will not meet 
or contact the patients will prepare a remote web- based 
randomisation system using random blocks of 8, 6 or 4 to 
ensure concealment of allocation. Participants and their 
GP will be informed about the outcome of the randomis-
ation by phone and participants will receive a patient card 
through mail detailing their treatment allocation and 
related procedures.
Blinding
The researcher who will carry out the primary analysis will 
be blinded for treatment allocation. The participant and 
the GP will not be blinded for treatment allocation. This 
is not feasible in this pragmatic trial.
Data collection methods
After obtaining informed consent, participants will 
complete the baseline questionnaire. Subsequently, the 
participants will be randomised to one of the two inter-
ventions groups. Participants will be asked to complete 
online questionnaires sent by email, after 6 weeks, 3, 6, 
9 and 12 months after randomisation. If the follow- up 
questionnaire is not returned within 2 weeks of initial 
mailing, a reminder will be sent encouraging the partic-
ipant to complete the questionnaire. Non- responders 
or responders with incomplete questionnaires will 
be contacted by telephone to pose them the missing 
questions.
Data management
Data management will be performed via a web- based 
medical survey tracker (Gemstracker). Each participant 
will be allocated a unique code, which will be used on all 
trial- specific documents, except for the signed informed 
consent and contact details. Participants’ identifiable 
data will be stored separately and securely from study data 
in accordance with local procedures.
Statistical methods
Baseline characteristics will be summarised using descrip-
tive statistics. All analyses will be performed under 
intention- to- treat.
Primary analyses
The primary clinical outcome is patient reported severity 
of pain and function over 12 months post randomisation, 
measured with the SPADI total score. A linear mixed 
model with repeated measures will be used to generate 
estimates of effects. The time points included in this 
model will be baseline, 6 weeks, 3, 6, 9 and 12 months. 
Baseline values for the primary outcome are retained 
as part of the outcome vector and group means on 
the primary outcome are assumed to be equal at base-
line (ie, an intervention- effect is restricted at baseline). 
Fixed effects will be time and time by treatment group. 
To model the covariance of repeated measures by partic-
ipant, the option for data structure in the analyses will 
be set on ‘unstructured’ and the model which yields the 
lowest Akaike’s information criterion will be chosen. The 
following baseline measurements will be considered as 
covariates: age, gender, duration of pain, concomitant 
neck pain and history of shoulder pain.28–30
Secondary analyses
The cost effectiveness will be evaluated using the incre-
mental cost per QALY gained of the corticosteroid injec-
tion versus physiotherapist- led exercise therapy, using 
both the healthcare as well as the societal perspective, 
using a time horizon of 12 months. Non- parametric boot-
strapping will be used to depict the degree of uncertainty 
for costs and health effects and the cost- utility ratio in 
a cost- effectiveness plane. In addition, an acceptability 
curve will be drawn, which indicates the probability that 
the intervention studied has lower incremental costs per 
QALY gained than various thresholds for the maximum 
willingness to pay for an extra QALY. Similar methods will 
be used to estimate the cost effectiveness of both inter-
ventions in the short term (6 weeks and 3 months) and 
medium term (6 and 9 months).
In addition, secondary analyses include shoulder pain- 
intensity, shoulder function, global perceived effect, 
quality of life, sleep quality, work absence, healthcare utili-
sation and side effects and will be evaluated at all follow- up 
time points using linear model regression methods for 
numerical outcomes and logistic regression methods for 
dichotomous outcomes. The clinical effectiveness at all 
other follow- up time points will be estimated using similar 
methods described for the primary analyses.
Subgroup analysis
Two explorative, pre- defined, subgroup analyses will 
be performed assessing the interaction effects between 
treatment and the severity of baseline pain (SPADI pain 
subscale) and between treatment and baseline function 
(SPADI function subscale) on the primary and secondary 
outcomes.
Sensitivity analysis
To test the robustness of the results sensitivity analysis will 
be performed using per- protocol principles (excluding 
participants with cross- over during the study period) and 
using complete cases only.
Data monitoring
This study has negligible risk according to the risk clas-
sification published in the guidelines of the Dutch 
Federation of University Medical Centres.31 Therefore, 
monitoring will take place once a year by independent 
monitors and no Data Monitoring Committee will be 
assigned to this study. Trial conduct and data integrity will 
be audited once per year by independent auditors.
Harms
Potential adverse events will be monitored using patient 
self- report questionnaires, contact with the SIX research 
team and GP reports. GPs and physiotherapists will 
be asked to report any SAE and suspected unexpected 
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serious adverse reaction (SUSAR) directly to the SIX 
research team. The SIX research team will report the 
SAE or SUSAR to the the Medical Research and Ethics 
Committee (METC).
Patient and public involvement
Prior to the design of this trial, patients who recently 
consulted their GP for shoulder pain were contacted to 
participate in our patient panel. These patients could 
comment on the design and confirmed this study as rele-
vant and feasible. The patient panel will also be used to 
help facilitate dissemination of the final results to trial 
participants and in the design of implementation strate-
gies towards patients.
ETHICS AND DISSEMINATION
Ethics approval and informed consent
Ethical approval on this protocol (V.3.0) was obtained on 
18 September 2020 by the METC of Erasmus MC Univer-
sity Medical Center Rotterdam (MEC 2020-0300). Any 
substantial amendment made to the protocol by the coor-
dinating investigator is sent to the METC for approval, 
prior to implementation. All participants will give written 
informed consent prior to data collection (online supple-
mental file).
Dissemination
Results of this trial will be published in peer- reviewed jour-
nals, as a double publication in a national GPs journal, 
to the Royal Dutch Society for Physiotherapy (KNGF), 
and through social media. A patient panel composed by 
the research team consisting of patients with shoulder 
pain will help facilitate the optimisation of the method 
of dissemination of the results to participating patients. 
Furthermore, participating GPs and physiotherapist will 
be informed about trial results (expected in 2023).
DISCUSSION
This paper presents the design of a pragmatic, RCT that 
will assess the effectiveness of corticosteroid injection 
versus physiotherapist- led exercise therapy for shoulder 
pain in primary care. Furthermore, this trial will assess 
the cost effectiveness of both interventions from a soci-
etal and healthcare perspective. The primary outcome is 
shoulder pain- intensity and function measured with the 
SPADI over a 12- month period. Secondary outcomes are 
measured at 6 weeks, 3, 6, 9 and 12 months follow- up 
and include shoulder pain- intensity, shoulder function, 
global perceived effect, quality of life, sleep quality, work 
absence, healthcare utilisation and adverse reactions. 
Between group differences for the primary outcome will 
be evaluated using a repeated measurements analysis with 
linear mixed models. An economic evaluation will be 
performed using a cost- utility analysis with quality of life. 
The outcomes of this trial may impact the clinical guide-
line recommendations for the management of shoulder 
pain in primary care and possibly the reimbursement of 
physiotherapy for patients with shoulder pain. Recruit-
ment of eligible patients is currently ongoing (November 
2020). Substantial protocol amendments will be commu-
nicated to participants, cooperating GPs and physiothera-
pist, the METC, the Dutch Trial Registry, ZonMw and the 
journal publishing this protocol.
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